文献速递淋巴瘤

高危套细胞淋巴瘤(高危MIPI-c或高p53表达)患者的临床结局

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
PubMed 文献 · Leukemia · 2023-07-26

基于欧洲MCL-Younger与MCL-Elderly前瞻性试验的684例可评估患者,将高危MIPI-c或p53表达>50%定义为高危疾病(HRD),其余为低危疾病(LRD)。HRD组中位无失败生存(1.1 vs 5.6年,p<0.0001)和总生存(2.2 vs 13.2年,p<0.0001)均显著短于LRD组,并在意大利MCL0208与北欧MCL4验证队列中得到证实。

要点

  • 高危MIPI-c或p53表达>50%定义的高危套细胞淋巴瘤患者预后极差。
  • HRD组中位FFS 1.1年、OS 2.2年,均显著短于LRD组。
  • 结果提示该高危亚组当前标准治疗不足,需要新型治疗策略。

核心结论

  • 高危MIPI-c或p53表达>50%定义的高危疾病(HRD)患者预后显著差于低危疾病(LRD)患者。
  • 结果提示该HRD亚组患者接受当前标准治疗不足,需要新型治疗策略。

研究设计与样本

  • 研究纳入来自前瞻性欧洲MCL-Younger和MCL-Elderly试验的684例可评估患者。
  • 高危疾病(HRD)定义为高危MIPI-c或p53表达>50%,低危疾病(LRD)定义为低危、低中危或高中危MIPI-c且p53表达≤50%。
  • 在意大利MCL0208和北欧MCL4试验的两个验证队列中对主要差异进行验证。

主要发现

  • HRD组中位无失败生存(FFS)为1.1年,LRD组为5.6年(p<0.0001)。
  • HRD组中位总生存(OS)为2.2年,LRD组为13.2年(p<0.0001)。
  • 上述主要差异在意大利MCL0208和北欧MCL4两个验证队列中得到证实。

关键数值与推荐

  • 高危疾病(HRD)定义:高危MIPI-c或p53表达>50%。
  • 低危疾病(LRD)定义:低危、低中危或高中危MIPI-c且p53表达≤50%。
  • HRD组中位FFS 1.1年 vs LRD组5.6年(p<0.0001)。
  • HRD组中位OS 2.2年 vs LRD组13.2年(p<0.0001)。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, treatment allocation of patients with Mantle Cell Lymphoma (MCL) is mainly based on age and medical fitness. The combined MCL International Prognostic Index (MIPI-c) allows to predict prognosis using clinical factors (MIPI) and the Ki-67 index. However, high p53 expression as surrogate for TP53 alterations has demonstrated to be an independent predictor for poor outcome. We aimed to define a clear high-risk group based on the combination of MIPI, Ki-67 and p53 expression/TP53 alteration. A total of 684 patients from the prospective European MCL-Younger and MCL-Elderly trials were evaluable. The classification of high-risk disease (HRD) as high-risk MIPI-c or p53 expression >50% versus low-risk disease (LRD) as low, low-intermediate or high-intermediate MIPI-c and p53 expression ≤50% allowed to characterize two distinct groups with highly divergent outcome. Patients with HRD had significantly shorter median failure-free survival (FFS) (1.1 vs. 5.6 years, p < 0.0001) and overall survival (OS) (2.2 vs. 13.2 years, p < 0.0001) compared to those with LRD. These major differences were confirmed in two validation cohorts from the Italian MCL0208 and the Nordic-MCL4 trials. The results suggest that this subset of HRD patients is not sufficiently managed with the current standard treatment and is asking for novel treatment strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Scheubeck G, Jiang L, Hermine O, et al. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023. PMID: 37495776. doi:10.1038/s41375-023-01977-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。